Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Business

Elite Traders Group Issues Report on Hot Biotech Stocks: (NYSE MKT: HEB), (NASDAQ: ROSG), (OTCQB: AMBS) and (OTCQB: SBFM)


Print article Print article
© Marketwire 2012
2012-12-10 21:33:17 -

NEW YORK, NY -- (Marketwire) -- 12/10/12 -- Elite Traders Group Issues Hot Biotech Report: HemispherxBioPharma, Inc. (NYSE MKT: HEB), Rosetta Genomics, Ltd. (NASDAQ: ROSG), Amarantus Bioscience, Inc. (OTCQB: AMBS), Sunshine Biopharma Inc. (OTCQB: SBFM)



About Elite Traders Group LLC and Firstpennypicks.com:
http://www.Firstpennypicks.com : www.firstpennypicks.com/ was developed as a beacon of hope in the penny stock newsletter industry. By remaining 100% uncompensated we are able to hand pick all of our alerts as opposed to paid biased advertising. This is why we are the fastest growing community of micro-cap traders on the web.



HemispherxBioPharma, Inc. (NYSE MKT: HEB) is a pharmaceutical. Hemispherx's flagship products include Alferon N Injection® (FDA approved for a category of sexually transmitted diseases) and the experimental therapeutics Ampligen® and Alferon® LDO.





Market Cap: $110 million
Shares Outstanding: 151 million
52 week price range: $1.10-$.1845
Average daily volume: 2.5 million shares



The FDA has tentatively scheduled a meeting of the Arthritis Advisory Committee, on December 20th, for review of the Company's Ampligen product for the treatment of Chronic Fatigue Syndrome. The FDA has a goal date of February 13, 2013 to complete its review. HEB shares have declined in recent trading but are still up 350% from the 52 week low. To receive early alerts on money makers like this subscribe to our VIP membership service. (Get Free Trend Analysis) http://www.firstpennypicks.com/get-your-free-research-report/ : www.firstpennypicks.com/get-your-free-research-report/



Rosetta Genomics, Ltd. (NASDAQ: ROSG), is a developer and provider of microRNA-based molecular diagnostic assays with the ability to diagnose and differentiate between the four most common lung and kidney tumor types. Rosetta shares have a 52 week range of $23.43-$1.40. The high end of the price range resulted from a three month spike over the summer with the low end preceding that spike. The share price has been fairly steady in the $4-$6 range since August. The company filed a SEC F-3 on December 7th indicating the possibility of issuing new securities. Rosetta's lung diagnostic tools were recently approved in New York State, giving the company's product access to all 50 states. For daily updates like this get a free subscription to our newsletter. (Get Free Trend Analysis) http://www.firstpennypicks.com/get-your-free-research-report/ : www.firstpennypicks.com/get-your-free-research-report/



Amarantus Bioscience, Inc. (OTCQB: AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury. AMBS has a market cap of $6.6 million with 224 million shares outstanding. The average daily trading volume is 15 million shares. The company filed SEC 8-k on November 27th releasing data from independent reviews of its technologies. AMBS has announced that it will be presenting at the OneMedForum 2013 healthcare conference on Tuesday, January 8th. In the past three months AMBS shares have risen in price 700% with a spike of 1600 %. Firstpennypicks.com alerts its VIP members to opportunities like this every week. Subscribe now. (Get Free Trend Analysis) http://www.firstpennypicks.com/get-your-free-research-report/ : www.firstpennypicks.com/get-your-free-research-report/



Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. Today the company announced a study on its flagship product's effectiveness. SBFM has now shown its product to be effective against three types of cancer that other chemotherapies are ineffective against.



Market cap: $11 million
Shares outstanding: 51 million
52 week average: $.79-$.141
Average trading volume: 48 thousand daily.



Take a look at the company's SEC 8-k filed on November 29th to get a detailed update on the status of their products. SBFM shares are up 50% in less than a month. Get a free subscription to the firstpennypicks.com newsletter where shares like these are covered all the time. (Get Free Trend Analysis) http://www.firstpennypicks.com/get-your-free-research-report/ : www.firstpennypicks.com/get-your-free-research-report/



To Receive More Reports like this one Subscribe free at http://www.FirstPennyPicks.com : www.firstpennypicks.com/



VIP Group



Increase Your Day Trading Profits by joining our VIP Pre-promotion/Early Alert Membership For only $29.95/month: http://www.firstpennypicks.com/vip-membership/ : www.firstpennypicks.com/vip-membership/



We do not accept compensation for any of the companies profiled in our Newsletter
Please note that all media from and FirstPennyPicks.com is investment opinion only. Elite Traders Group employees are not registered as an Investment Adviser in any jurisdiction whatsoever. This advertisement is for informational purposes only and is not intended to be a recommendation to buy or sell securities in any of the profiled companies listed here.



COMPARE OUR FULL DISCLAIMER WITH ANY OTHER NEWSLETTER AT http://www.firstpennypicks.com/disclaimer/ : www.firstpennypicks.com/disclaimer/




Contact:
Elite Traders Group LLC
Email Contact : www2.marketwire.com/mw/emailprcntct?id=DBFE6ABC4456EDBC



Press Information:




Contact Person:


Disclaimer: (c) 2014 Market Wire. All of the press releases contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Market Wire's, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com | BidVertiser